

Clinical trials of recombinant human erythropoietin beta

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
recombinant human erythropoietin beta vs placebo			
REVIVAL-3 [NCT00390832] n=NA follow-up:	recombinant human erythropoietin beta 33.333 IU given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) versus placebo	patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention	double-blind Germany

More details and results :

- increasing hemoglobin concentration for acute myocardial infarction in patients undergoing PCI at <http://www.trialresultscenter.org/go-Q470>

References

REVIVAL-3, :

Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. *Circ Cardiovasc Interv* 2010;3:408-13 [20736448] [10.1161/CIRCINTERVENTIONS.109.904425](https://doi.org/10.1161/CIRCINTERVENTIONS.109.904425)

Stappich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord* 2017;17:38 [28109258]

Stappich B, Groha P, Ibrahim T, Schunkert H, Laugwitz KL, Hadamitzky M, Kastrati A, Ott I Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. *BMC Cardiovasc Disord* 2017;17:38 [28109258]